<DOC>
	<DOC>NCT02066961</DOC>
	<brief_summary>The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and trigger(s) for treatment changes and to document healthcare resource utilization used to manage treatment-related complications.</brief_summary>
	<brief_title>A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer</brief_title>
	<detailed_description>Each subject will be followed from the time of enrollment for a minimum of 3 years and a maximum of up to 6 years or until death, whichever comes first.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Diagnosis of prostate adenocarcinoma Will receive a new intervention at the time of study entry, for the treatment of: Biochemical failure after initial curativeintent surgery (radical prostatectomy) or radiotherapy (externalbeam radiation therapy, brachytherapy, or both) and a PSA doubling time of one year or less or a confirmed PSA of â‰¥ 50 ng/mL (2 consecutive values) within 6 months prior to study entry; or Castrationresistant prostate cancer; or Metastatic prostate cancer at initial diagnosis of prostate cancer Prior treatment of metastatic castrationresistant prostate cancer with systemic chemotherapy Life expectancy of &lt;1 year due to comorbidities</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>castration-resistant prostate cancer</keyword>
	<keyword>prostate cancer</keyword>
</DOC>